ストックスクリーナーアプリを入手
0.5949
0.85%
-0.0051
アフターアワーズ：
.59
-0.0049
-0.82%
前日終値:
$0.60
開ける：
$0.5817
24時間の取引高:
675.09K
Relative Volume:
0.17
時価総額：
$35.40M
収益：
$950.10K
当期純損益:
$-16.69M
株価収益率:
-0.7167
EPS:
-0.83
ネットキャッシュフロー:
$-15.16M
1週間 パフォーマンス:
-12.35%
1か月 パフォーマンス:
-16.22%
6か月 パフォーマンス:
-33.90%
1年 パフォーマンス:
-45.42%
1日の値動き範囲:
$0.57
$0.6035
1週間の範囲:
$0.57
$0.6698
52週間の値動き範囲:
$0.3067
$1.80
Femasys Inc Stock (FEMY) Company Profile
FEMY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.5949 | 35.70M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
525.04 | 187.46B | 10.06B | 2.88B | 2.27B | 7.8807 |
|
BDX
Becton Dickinson Co
|
203.40 | 57.96B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.87 | 39.68B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
46.31 | 37.32B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
255.50 | 37.29B | 5.26B | 1.44B | 1.76B | 9.7713 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-20 | 開始されました | Laidlaw | Buy |
Femasys Inc (FEMY) 最新ニュース
Travel Stocks: What is PCARs revenue forecastEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Returns Recap: Does Ares Management Corporation meet Warren Buffetts criteria2025 Earnings Impact & Growth Oriented Trading Recommendations - baoquankhu1.vn
Femasys Receives Nasdaq Extension to Regain Listing Compliance - The Globe and Mail
Femasys granted 180-day extension by Nasdaq to meet minimum bid price rule - Investing.com
Femasys Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Stock Recap: Will FUFU benefit from geopolitical trendsCPI Data & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Sahm
Femasys receives 180-day Nasdaq extension to meet minimum bid price - Investing.com Nigeria
Femasys secures Nasdaq extension to regain bid price compliance - MSN
Femasys Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Requirement - TradingView
Nasdaq gives Femasys more time to fix sub-$1 share price by July 2026 - Stock Titan
Femasys partners with Refuah Health Center to expand FemaSeed fertility treatment - Investing.com Nigeria
Dow Update: Why Femasys Inc stock attracts global investorsTrade Volume Summary & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Femasys Inc. Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed®? in Community-Based Care - marketscreener.com
Femasys Inc. Partners with Refuah Health Center to Enhance Accessibility of FemaSeed for Infertility Treatment - Quiver Quantitative
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care - The Manila Times
Will Femasys Inc. stock maintain growth storyGap Up & Reliable Breakout Stock Forecasts - ulpravda.ru
What valuation multiples suggest for Femasys Inc. stockJuly 2025 Update & Safe Capital Growth Stock Tips - Улправда
Published on: 2026-01-09 05:32:45 - Улправда
Can Femasys Inc. stock rebound after recent weaknessPortfolio Return Report & Expert Approved Trade Ideas - Улправда
How Femasys Inc. stock performs after earnings2025 Price Momentum & Weekly High Momentum Picks - Улправда
Jonathan Schechter buys PharmaCyte Biotech shares worth $48,232 By Investing.com - Investing.com Nigeria
How Femasys Inc. stock reacts to inflationary pressures2026 world cup usa national team group stage goalkeepers counter attacking expert forecast guide - ulpravda.ru
Earnings Beat: Will MARZ stock keep high P E multiples2025 Biggest Moves & Pattern Based Trade Signal System - moha.gov.vn
Femasys gains UK approval for women's health products - MSN
Market Leaders: How strong is Femasys Inc stock balance sheetQuarterly Earnings Summary & AI Forecast for Swing Trade Picks - Bộ Nội Vụ
User | theeveningleader.comFemasys Inc.Common Stock (Nasdaq:FEMY) Stock Quote - FinancialContent
Femasys files for at-the-market offering of up to $9.8 million in common stock - Investing.com Australia
Femasys Launches At-the-Market Common Stock Offering - TipRanks
Femasys files for at-the-market offering of up to $9.8 million in common stock By Investing.com - Investing.com South Africa
Femasys Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Suwanee company Femasys Inc. gets FDA approval for diagnostic device - The Business Journals
Contemporary OB/GYN week in review: FemVue clearance, flibanserin approval, and more - Contemporary OB/GYN
Swing Trade: Why Femasys Inc. stock is a must watch in 20252025 Geopolitical Influence & Accurate Intraday Trading Signals - Улправда
What momentum indicators show for Femasys Inc. stockMarket Sentiment Review & Risk Managed Trade Strategies - Bölüm Sonu Canavarı
Why Femasys Inc. stock is rated strong buyJuly 2025 Momentum & Real-Time Volume Spike Alerts - Улправда
Femasys receives FDA clearance for FemVue Controlled diagnostic device By Investing.com - Investing.com Australia
How interest rate cuts could boost Femasys Inc. stockMarket Growth Review & Technical Entry and Exit Tips - Bölüm Sonu Canavarı
How strong is Femasys Inc. stock balance sheet2025 Trading Recap & Consistent Profit Focused Trading Strategies - DonanımHaber
Why Femasys Inc. stock is a must watch in 20252025 Market Sentiment & Growth Oriented Trade Recommendations - Улправда
What analyst consensus says on Femasys Inc. stockJuly 2025 Action & AI Powered Market Trend Analysis - DonanımHaber
Femasys Earnings Notes - Trefis
PharmaCyte Biotech (Nasdaq: PMCB) reports Q2 loss and details QCLS, Femasys deals - Stock Titan
Femasys Inc. Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - marketscreener.com
FDA clears FemVue Controlled for in-office tubal assessment - Contemporary OB/GYN
Femasys secures U.S. FDA clearance for next-generation Femvue diagnostic device - marketscreener.com
Femasys Gains FDA Clearance for FemVue Diagnostic Device - TipRanks
Femasys gains FDA clearance for FemVue diagnostic device - MSN
Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device - The Manila Times
Femasys Inc (FEMY) 財務データ
収益
当期純利益
現金流量
EPS
0.36%
0.01%
大文字化:
|
ボリューム (24 時間):